Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects-Reference-Cited by-同舟云学术

Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Oral Doses of Tegoprazan in Healthy Chinese Subjects

Published:2020-12-23 Issue:1 Volume:41 Page:89-97
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

He Jinjie,Cao Guoying,Yu Jicheng,Wang Jingjing,Cheng Nengneng,Wu Jufang,Zhang Jing^ORCID,Wu Xiaojie,Zhang Basheng,Lu Jiayan,Chen Shangzhi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40261-020-00986-4.pdf

Reference16 articles.

1. Devault KR, Talley NJ. Insights into the future of gastric acid suppression. Nat Rev Gastroenterol Hepatol. 2009;6(9):524–32.

2. Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2014;2(3):295–314.

3. Shin JM, Vagin O, Munson K, et al. Molecular mechanisms in therapy of acid-related diseases. Cell Mol Life Sci. 2008;65(2):264–81.

4. Fock KM, Ang TL, Bee LC, et al. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet. 2008a;47(1):1–6.

5. CheyWd MRCL. Nighttime symptoms and sleep impairment among patients with gastro-esophageal reflux disease (GERD) receiving prescription (Rx) proton pump inhibitors (PPIs). Gastroenterology. 2008;134(4 Suppl. 1):A323–4.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Vitro Metabolism and Transport Characteristics of Zastaprazan;Pharmaceutics;2024-06-13

2. Tegoprazan as a New Remedy for Gastrointestinal Diseases in Comparison with its Therapeutic Predecessors: A Mini-Review;Current Drug Research Reviews;2024-03

3. The Effect of Tegoprazan on the Treatment of Endoscopic Resection-Induced Artificial Ulcers: A Multicenter, Randomized, Active-Controlled Study;Gut and Liver;2024-02-22

4. Enhancing drug administration flexibility: evaluation of pharmacokinetic properties of tegoprazan orally disintegrating tablet (ODT) administered via nasogastric tube or oral dosing;Translational and Clinical Pharmacology;2024

5. Progress of Potassium-Competitive Acid Blocker Tegoprazan in the Treatment of Acid-Related Diseases;Advances in Clinical Medicine;2024